EMA Clarifies Approach to Pharmacovigilance Fees in Revised Q&A Guidance By Sam | February 14, 2017 The EMA revised Q&A guidance on pharmacovigilance fees, clarifying which sponsors and assessments are subject to charges. Source: Drug Industry Daily Posted in Drug Industry Daily